Pfizer, CFF Focus On Possible Combination Approach To Treating CF’s Underlying Cause
This article was originally published in The Pink Sheet Daily
Building upon CFTR-focused drugs pioneered by Vertex’s Kalydeco, Pfizer will receive up to $58 million in R&D funding from the Cystic Fibrosis Foundation to bring new CF candidates into the clinic.
You may also be interested in...
Children’s Tumor Foundation is pursuing an industry partnership model with the message that there may be drug development opportunities beyond the rare disease area.
Pfizer CMO Freda Lewis-Hall acknowledged FDA’s current activities to promote patient-centered research, but called on the agency to lead in developing guidance to help industry be more proactive in incorporating patients into its research.
Pfizer’s partnership with the Alliance for Lupus Research to co-fund translational projects within the context of the pharma’s CTI program is a first. It’s a novel way to speed promising science into the clinic. But can Pfizer, a non-profit research foundation, and academic researchers reconcile their new roles and variant cultures to make the model work?